{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:16:04Z","timestamp":1792145764805,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mayocp.2025.01.018","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T18:03:17Z","timestamp":1742752997000},"page":"2152-2171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"Vikash","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-9880","authenticated-orcid":false,"given":"Song Peng","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-6338","authenticated-orcid":false,"given":"Aanchal","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-8358","authenticated-orcid":false,"given":"Novonil","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-1236","authenticated-orcid":false,"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-6779","authenticated-orcid":false,"given":"Dan","family":"Gaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-4212","authenticated-orcid":false,"given":"Zeljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-6473","authenticated-orcid":false,"given":"Ivan","family":"Pe\u0107in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1911","authenticated-orcid":false,"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-1489","authenticated-orcid":false,"given":"Peter E.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-5460","authenticated-orcid":false,"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.mayocp.2025.01.018_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2025.01.018_bib2","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart Disease and Stroke Statistics\u20142023 Update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.mayocp.2025.01.018_bib3","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The Global Burden of Cardiovascular Diseases and Risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.01.018_bib4","first-page":"559","article-title":"A look to the past \u2013 what has had the biggest impact on lipids in the last four decades? a personal perspective","volume":"19","author":"Banach","year":"2023","journal-title":"Arch Med Sci"},{"issue":"34","key":"10.1016\/j.mayocp.2025.01.018_bib5","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"10355","key":"10.1016\/j.mayocp.2025.01.018_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(22)01643-9","article-title":"Statin intolerance: time to stop letting it get in the way of treating patients","volume":"400","author":"Banach","year":"2022","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.mayocp.2025.01.018_bib7","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"34","key":"10.1016\/j.mayocp.2025.01.018_bib8","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocp.2025.01.018_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","article-title":"A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin","volume":"235","author":"Ran","year":"2017","journal-title":"Int J Cardiol"},{"issue":"25","key":"10.1016\/j.mayocp.2025.01.018_bib10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2025.01.018_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.12997\/jla.2021.10.3.291","article-title":"Comparison of the effects of high-intensity statin therapy with moderate-intensity statin and ezetimibe combination therapy on major adverse cardiovascular events in patients with acute myocardial infarction: a nationwide cohort study","volume":"10","author":"Kim","year":"2021","journal-title":"J Lipid Atheroscler"},{"issue":"6","key":"10.1016\/j.mayocp.2025.01.018_bib12","first-page":"1429","article-title":"2022: The year in cardiovascular disease - the year of upfront lipid lowering combination therapy [editorial]","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"issue":"15","key":"10.1016\/j.mayocp.2025.01.018_bib13","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.mayocp.2025.01.018_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.mayocp.2025.01.018_bib15","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1185\/030079907X210507","article-title":"Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy","volume":"23","author":"Mikhailidis","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"10349","key":"10.1016\/j.mayocp.2025.01.018_bib16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2025.01.018_bib17","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2025.01.018_bib18","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2025.01.018_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.01.018_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.mayocp.2025.01.018_bib21","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.mayocp.2025.01.018_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.mayocp.2025.01.018_bib23","series-title":"Stata Statistical Software: Release 18","year":"2023"},{"issue":"5","key":"10.1016\/j.mayocp.2025.01.018_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacc.2023.05.042","article-title":"Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention","volume":"82","author":"Lee","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248412445506","article-title":"Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study","volume":"18","author":"Kouvelos","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2025.01.018_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS Trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.mayocp.2025.01.018_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.carrev.2016.11.010","article-title":"Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: intravascular ultrasound with iMap; the OCTIVUS trial","volume":"18","author":"Hougaard","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1253\/circj.CJ-11-0730","article-title":"Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study","volume":"76","author":"Kovarnik","year":"2012","journal-title":"Circ J"},{"issue":"18","key":"10.1016\/j.mayocp.2025.01.018_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030414","article-title":"Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL-ACS data","volume":"12","author":"Lewek","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.mayocp.2025.01.018_bib31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1753944713513222","article-title":"Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients","volume":"7","author":"Suzuki","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib32","article-title":"Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI","volume":"2021","author":"Sun","year":"2021","journal-title":"J Interv Cardiol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.01.018_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1253\/circj.CJ-17-0598","article-title":"Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome","volume":"82","author":"Hibi","year":"2018","journal-title":"Circ J"},{"issue":"29","key":"10.1016\/j.mayocp.2025.01.018_bib34","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.mayocp.2025.01.018_bib35","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.mayocp.2025.01.018_bib36","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.mayocp.2025.01.018_bib37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10106","key":"10.1016\/j.mayocp.2025.01.018_bib38","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2025.01.018_bib39","first-page":"1602","article-title":"2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies: can we render dyslipidemia a rare disease by 2024?","volume":"19","author":"Banach","year":"2023","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.mayocp.2025.01.018_bib40","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/DDDT.S332352","article-title":"Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights","volume":"16","author":"Chilbert","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2025.01.018_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.01.018_bib42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14740\/cr1224","article-title":"Effect of ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels: a meta-analysis","volume":"12","author":"Lee","year":"2021","journal-title":"Cardiol Res"},{"issue":"14","key":"10.1016\/j.mayocp.2025.01.018_bib43","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.","volume":"80","author":"Writing Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.mayocp.2025.01.018_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.mayocp.2025.01.018_bib46","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.phrs.2018.12.002","article-title":"Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes \u2013 data from the TERCET registry with 19,287 patients","volume":"139","author":"Dyrbus","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.mayocp.2025.01.018_bib47","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"10.1016\/j.mayocp.2025.01.018_bib48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocp.2025.01.018_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a Position Paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.mayocp.2025.01.018_bib50","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.mayocp.2025.01.018_bib51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/HCO.0000000000000305","article-title":"IMPROVE-IT: what have we learned?","volume":"31","author":"Banach","year":"2016","journal-title":"Curr Opin Cardiol"},{"issue":"19","key":"10.1016\/j.mayocp.2025.01.018_bib52","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.mayocp.2025.01.018_bib53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.mayocp.2025.01.018_bib54","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","article-title":"Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d)","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.01.018_bib55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3803\/EnM.2018.33.2.219","article-title":"Comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes: a meta-analysis","volume":"33","author":"Hong","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"10.1016\/j.mayocp.2025.01.018_bib56","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/eurheartj\/ehac709","article-title":"Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial","volume":"44","author":"Lee","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.mayocp.2025.01.018_bib57","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1161\/CIRCRESAHA.119.315233","article-title":"Statin toxicity: mechanistic insights and clinical implications [letter reply]","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.mayocp.2025.01.018_bib58","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.atherosclerosis.2012.09.001","article-title":"Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients","volume":"225","author":"Thongtang","year":"2012","journal-title":"Atherosclerosis"},{"issue":"28","key":"10.1016\/j.mayocp.2025.01.018_bib59","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaa531","article-title":"Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease","volume":"41","author":"Helgadottir","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2025.01.018_bib60","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/CIRCGENETICS.109.907873","article-title":"Genetic regulation of serum phytosterol levels and risk of coronary artery disease","volume":"3","author":"Teupser","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"issue":"22","key":"10.1016\/j.mayocp.2025.01.018_bib61","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","author":"Myocardial Infarction Genetics Consortium Investigators","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2025.01.018_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043714","article-title":"Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients","volume":"11","author":"Davis","year":"2021","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.mayocp.2025.01.018_bib63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.01.018_bib64","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.mayocp.2025.01.018_bib65","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don\u2019t physicians follow clinical practice guidelines? a framework for improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.mayocp.2025.01.018_bib66","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/CIRCULATIONAHA.105.169180","volume":"112","author":"Fletcher","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001891","article-title":"Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus","volume":"9","author":"Garc\u00eda-Ulloa","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.mayocp.2025.01.018_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.23935","article-title":"Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","volume":"46","author":"Desai","year":"2023","journal-title":"Clin Cardiol"}],"updated-by":[{"DOI":"10.1016\/j.mayocp.2025.10.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:46:34Z","timestamp":1764578794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0025619625000758"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.01.018","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}